Chinese scientists have conducted a comprehensive proteomic analysis of lung adenocarcinoma, a major lung cancer. They did this to understand the pathological mechanism of the disease and plan precise treatments.

Jointly conducted by researchers from the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences (CAS) and the cancer hospital of the Chinese Academy of Medical Sciences, as well as other institutions, the research was published in the journal Cell.

The proportion of non-smokers among lung adenocarcinoma patients is significantly higher than in other types of lung cancer, and the pathogenesis of lung adenocarcinoma is more complex. A comprehensive proteomic study of lung adenocarcinoma is key to understanding the disease, discovering drug targets, and developing treatments.

Researchers spent more than six years carrying out comprehensive proteomic analyses of tumor tissues from 103 lung adenocarcinoma patients through interdisciplinary research of proteomics, bioinformatics, cancer biology, and clinical medicine.

They obtained a comprehensive molecular landscape of the disease, revealed molecular characteristics closely related to the prognosis of patients, and identified two major gene mutations of lung adenocarcinoma in the Chinese population.

Tan Minjia, one of the researchers, said the study provides drug targets and prognostic biomarkers which are expected to be applied clinically for the treatment of lung adenocarcinoma. It has application value in guiding patients' clinical medication and improving survival times.

He Fuchu, Member of CAS, said the research marks an important achievement of the China Human Proteome Project and indicates the importance of proteomics in precision medicine.

For more information, please contact:

Prof. Tan Minjia

E-mail: mjtan@simm.ac.cn

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Source: Xinhua